SLS Stock Surges Past $25 on AML News
SLS stock hit a 5-year high above $25 as retail traders anticipate a key AML readout.
June 30, 2026
1 min read
14 views
Source: newsable.asianetnews.com
Image: newsable.asianetnews.com
Shares of SELLAS Life Sciences Group (SLS) surged past $25 on June 30, 2026, reaching a five-year high, driven by retail investor enthusiasm ahead of an anticipated readout from the company's acute myeloid leukemia (AML) clinical trial.
The stock closed at $25.47, up 12% on the day, with trading volume more than double the average. Retail traders on platforms like Reddit's WallStreetBets have been betting on a positive outcome from the Phase 3 trial of SLS's lead drug candidate, GPS, for AML.
Analysts note that the upcoming data readout, expected in July 2026, could be a major catalyst. If positive, it may lead to a regulatory submission for approval. However, the stock remains volatile, and some caution that expectations are high.
❓ Frequently Asked Questions
What caused SLS stock to surge above $25?
The surge was driven by retail investor anticipation of a key clinical trial readout for SLS's AML drug candidate, GPS, expected in July 2026.
What is the significance of the AML readout for SLS?
The Phase 3 trial readout for GPS in acute myeloid leukemia is a major catalyst that could lead to regulatory submission if positive.
Is SLS stock considered risky?
Yes, biotech stocks are volatile, and the high expectations around the AML readout could lead to significant price swings.
